TCWP’s Meridian Bioscience Inc VIVO Stock Holding History

TCWP’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-384	Closed	-$9K	–	1936
2022 Q1	$9K	Buy	+384	New	+$9.13K	﹤0.01%	931

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VLKIM

Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

TCWP's VIVO Position: Q2 2022 in Review

TCWP sold out of Meridian Bioscience Inc (VIVO) in Q2 2022, closing a stake of 384 shares — an estimated $9K sold.

TCWP first reported a position in VIVO in Q1 2022 and held it in 1 quarter. The position peaked at $9K in Q1 2022. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

TCWP reported no remaining Meridian Bioscience Inc position as of Q2 2022 after selling out during the quarter.
TCWP sold 384 Meridian Bioscience Inc shares in Q2 2022, an estimated $9K.
TCWP first reported a position in Meridian Bioscience Inc in Q1 2022 and held it in 1 quarter.
TCWP's Meridian Bioscience Inc position peaked at $9K in Q1 2022.
216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.